DOCSLIB.ORG

THE EDINBURGH GAZETTE 13 FEBRUARY 1987 197 (A) on Each

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
THE EDINBURGH GAZETTE 13 FEBRUARY 1987 197 (A) on Each THE EDINBURGH GAZETTE 13 FEBRUARY 1987 197 (a) on each occasion on which it is imported or exported, the Methylamphetamine 900mg quantity specified in respect of that drug in column 2 of the Methylamphetamine Hydrochloride 900mg Schedule to this licence; Methylamphetamine Saccharate 900mg (b) in any period of thirty days, twice that quantity. Methylphenidate Hydrochloride 900mg Methylphenobarbitone 9g 2. This licence does not apply: Methyprylone 6g (a) to any controlled drug which is not contained in a medicinal Metopon 1.35g product within the meaning of the Medicines Act 1968; Morphine Hydrochloride 1.2g Morphine Sulphate 1.2g (b) unless the controlled drug is under the direct personal Morphine Tartrate 1.2g supervision of the person importing or exporting it; Norpipanone Hydrochloride 270mg (c) to the exportation of any controlled drug by a person who is Oxycodone Hydrochloride 900mg not lawfully in possession of the drug. Oxycodone Pectinate 900mg Oxymorphone Hydrochloride 450mg It is hereby directed that, notwithstanding any provision in Pentazocine Hydrochloride 9g Regulations under Section 10 of the Misuse of Drugs Act, with respect to Pentazocine Lactate 5.4g record-keeping, no record is required to be kept of any quantity of Pethidine Hydrochloride 2.25g controlled drug imported or exported under this licence. Phenadoxone 2.25g This licence shall remain in force until revoked by Order of the Phenazocine 4SOmg Secretary of State, and the Department of Health and Social Services for Phendimatrazine Tartrate 3.2g Northern Ireland. Phenmetrazine Hydrochloride 1.25g Phentermine 450mg SCHEDULE Piminodine Esylate 4.5g Pipradrol Hydrochloride 90mg PARTI Piritramide 3.6g Column 1 Column 2 Piritramide Hydrogen Tartrate 3.6g 2.25g Maximum Quantity Propiram Fumarate Controlled Drugs Thebacon Hydrochloride 22Smg Alphaprodine 3.6g Tilidate Hydrochloride 6g Amphetamine 300mg Trimeperidine Hydrochloride 2.25g Amphetamine Phosphate 225mg The following 5, S-disubstituted Amphetamine Sulphate 225mg Barbituric Acids: Anhydrous Morphine 360mg Allobarbitone 3g Anileridine 900mg Amylobarbitone 9g Anileridine Hydrochloride 900mg Amylobarbitone Sodium 9g Anileridine Phosphate 900mg Aprobarbitone 7.5g Benzphetamine 2.25g Barbitone 9g Beritramide 450mg Barbitone Sodium 9g Chlorphentermine Hydrochloride 975mg Butalbital Cocaine Hydrocholoride, Nitrate 20ml at 4% 4ml Butallylonal or Sulphate Eyedrops maximum strength Butobarbitone 4.5g Cocaine Hydrochloride, Nitrate SOOmg Cyclobarbitone 6g or Sulphate as active ingredient Clyclobarbitone Calcium 6g in a mixture being used by a patient Cyclopentobarbitone 3g who is terminally ill. Heptabarbitone 6g Dexamphetamine 300mg Hexethal Sodium 18g Dexamphetamine Phosphate 150mg Ibomal 6g Dexamphetamine Sulphate 900mg Nealbarbitone 3g Dextromoramide Tartrate 900mg Pentobarbitone 3g Diamorphine Hydrochloride as an SOOmg Pentobarbitone Calcium 3g ingredient in a mixture or linctus Pentobarbitone Sodium 3g Diamorphine Hydrochloride Tablets 450 mg Phenobarbitone 2-7g Diamorphine Hydrochloride Ampoules 1.35g Phenobarbitone Sodium 12g Diamorphine Hydrochloride Elixir SOOmg Phenylmethylbarbituric acid 6g Diethylpropion Hydrochloride 1.125g Probarbitone Sodium 22.5g Dihydrocodeine Tartrate 3.6g Probarbitone Calcium 22.5g Dihydrocodeinone 0 - carboxymethyloxime ISOmg Proxibarbal 9g Dipipanone 600mg Quinalbarbitone 3g Drotebanol 90mg Quinalbarbitone Sodium 3g Ethchlorvynol 15g Secbutobarbitone 1.8g Ethinamate 15g Secbutobarbitone Sodium 1.8g Fentanyl Citrate 4Smg Talbutal 2.25g Glutethimide 7.5g Vinbarbitone 3g Hydrocodone Hydrochloride 675mg Vinbarbitone Sodium 3g Hydrocodone Phosphate 675mg Vinylbitone 3g Hydrocodone Tartrate 675mg Hydromorphone 360mg Ketobemidone 4SOmg SCHEDULE II Levorphanol Tartrate 135mg Mazindol 4Smg Column I Column 2 Mecloqualone 4.5g Controlled Drug Maximum Quantity Medicinal Opium 1.8g Mephentermine Sulphate 2.7g Anhydrous Morphine 360mg Meprobamate 3.6g Diamorphine Hydrochloride as an SOOmg Methadone Hydrochloride Ampoules SOOmg ingredient in a mixture or linctus Methadone Hydrochloride Linctus SOOmg Diamorphine Hydrochloride Tablets 450mg Methadone Hydrochloride Tablets SOOmg Diamorphine Hydrochloride Ampoules 1.35g Methadyl Acetate SOOmg Diamorphine Hydrochloride Elixir SOOmg Methaqualone 4.5g Morphine Sulphate 1.2g Methaqualone Hydrochloride 4.5g Pethidine Hydrochloride 2.25g.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.205,048 B2 Lichter Et Al
    USOO9205048B2 (12) United States Patent (10) Patent No.: US 9.205,048 B2 Lichter et al. (45) Date of Patent: *Dec. 8, 2015 (54) CONTROLLED RELEASE ANTIMICROBIAL (58) Field of Classification Search COMPOSITIONS AND METHODS FOR THE CPC A61 K9/0024; A61 K9/0046; A61K 31/497; TREATMENT OF OTC DSORDERS A61K 47/34 See application file for complete search history. (71) Applicants: Otonomy, Inc., San Diego, CA (US); The Regents of the University of California, Oakland, CA (US) (56) References Cited (72) Inventors: Jay Lichter, Rancho Santa Fe, CA (US); U.S. PATENT DOCUMENTS Andrew M. Trammel, Olathe, KS (US); 4,188,373 A 2, 1980 Krezanoski Fabrice Piu, San Diego, CA (US); 4,478,822 A 10, 1984 Haslam et al. Qiang Ye, San Diego, CA (US); Luis A. 4,938,763. A 7, 1990 Dunn et al. Dellamary, San Marcos, CA (US); Carl 4,968,507 A 11/1990 Zentner et al. 5,033,252 A 7, 1991 Carter Lebel, Malibu, CA (US); Jeffrey P. 5,052,558 A 10, 1991 Carter Harris, La Jolla, CA (US) 5,292,516 A 3/1994 Viegas et al. 5,323,907 A 6/1994 Kalvelage (73) Assignees: OTONOMY, INC., San Diego, CA 5,324,519 A 6/1994 Dunn et al. (US): THE REGENTS OF THE 5,421,818 A 6/1995 Arenberg UNIVERSITY OF CALIFORNLA, 5,474,529 A 12/1995 Arenberg 5,476,446 A 12/1995 Arenberg Oakland, CA (US) 5,503,848 A 4/1996 Perbellini et al. 5,702,716 A 12/1997 Dunn et al.
    [Show full text]
  • Perspectives in Drug Discovery a Collection of Essays on the History and Development of Pharmaceutical Substances
    Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology National Board of Forensic Medicine Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine Artillerigatan 12 • SE-587 58 Linköping • Sweden E-mail: [email protected] Internet: www.rmv.se RMV-report 2010:1 ISSN 1103-7660 Copyright © 2010 National Board of Forensic Medicine and Professor Alan Wayne Jones Design and graphic original: Forma Viva, Linköping • Sweden Printed by Centraltryckeriet, Linköping • Sweden, October 2010 Contents Preface Introduction 1. The First Sedative Hypnotics . 13 2. The Barbiturates ......................... 19 3. The Benzodiazepines ..................... 25 4. Narcotic Analgesics . 31 5. Central Stimulant Amines . 39 6. The First Antidepressants .................. 45 7. Antipsychotic Medication ................. 51 8. Aspirin and Other NSAID .................. 59 9. General Anesthetics . 65 10. SSRI Antidepressants . 71 11. Histamine Antagonists .................... 79 12. Anticonvulsants ......................... 87
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn Et Al
    US 2003.0068365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn et al. (43) Pub. Date: Apr. 10, 2003 (54) COMPOSITIONS AND METHODS FOR Related U.S. Application Data ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME BEADS (60) Provisional application No. 60/327,643, filed on Oct. 5, 2001. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); Tanusin Ploysangam, Bangkok (TH); Publication Classification Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok (51) Int. Cl." .......................... A61K 9/127; A61K 35/78 (TH); Nardo Zaias, Miami Beach, FL (52) U.S. Cl. ............................................ 424/450; 424/725 (US) (57) ABSTRACT Correspondence Address: Law Office of Eric G. Masamori Compositions and methods for administration of active 6520 Ridgewood Drive agents encapsulated within liposome beads to enable a wider Castro Valley, CA 94.552 (US) range of delivery vehicles, to provide longer product shelf life, to allow multiple active agents within the composition, (21) Appl. No.: 10/264,205 to allow the controlled use of the active agents, to provide protected and designable release features and to provide (22) Filed: Oct. 3, 2002 Visual inspection for damage and inconsistency. US 2003/0068365A1 Apr. 10, 2003 COMPOSITIONS AND METHODS FOR toxic degradation of the products, leakage of the drug from ADMINISTRATION OF ACTIVE AGENTS USING the liposome and the modifications of the Size and morphol LPOSOME BEADS ogy of the phospholipid liposome vesicles through aggre gation and fusion. Liposome vesicles are known to be CROSS REFERENCE TO OTHER thermodynamically relatively unstable at room temperature APPLICATIONS and can Spontaneously fuse into larger, leSS Stable altered liposome forms.
    [Show full text]
  • 201 PART 329—HABIT-FORMING DRUGS Subpart A—Derivatives
    Food and Drug Administration, HHS § 329.1 section 502(e) of the Federal Food, PART 329ÐHABIT-FORMING DRUGS Drug, and Cosmetic Act. (d) The statement expressing the Subpart AÐDerivatives Designated as amount (percentage) of alcohol present Habit Forming in the product shall be in a size reason- ably related to the most prominent Sec. printed matter on the panel or label on 329.1 Habit-forming drugs which are chem- which it appears, and shall be in lines ical derivatives of substances specified in generally parallel to the base on which section 502(d) of the Federal Food, Drug, the package rests as it is designed to be and Cosmetic Act. displayed. (e) For a product to state in its label- Subpart BÐLabeling ing that it is ``alcohol free,'' it must 329.10 Labeling requirements for habit- contain no alcohol (0 percent). forming drugs. (f) For any OTC drug product in- tended for oral ingestion containing Subpart CÐExemptions over 5 percent alcohol and labeled for use by adults and children 12 years of 329.20 Exemption of certain habit-forming age and over, the labeling shall contain drugs from prescription requirements. the following statement in the direc- AUTHORITY: 21 U.S.C. 352, 353, 355, 371. tions section: ``Consult a physician for use in children under 12 years of age.'' SOURCE: 39 FR 11736, Mar. 29, 1974, unless (g) For any OTC drug product in- otherwise noted. tended for oral ingestion containing over 0.5 percent alcohol and labeled for Subpart AÐDerivatives use by children ages 6 to under 12 years Designated as Habit Forming of age, the labeling shall contain the following statement in the directions § 329.1 Habit-forming drugs which are section: ``Consult a physician for use in chemical derivatives of substances children under 6 years of age.'' specified in section 502(d) of the (h) When the direction regarding age Federal Food, Drug, and Cosmetic in paragraph (e) or (f) of this section Act.
    [Show full text]
  • Laws and Regulations Promulgated to Give Effect to the Provisions of the International Treaties on Narcotic Drugs and Psychotropic Substances
    E/NL. 1977/26-28 20 March 1979 UNITED NATIONS ENGLISH AND SPANISH ONLY LAWS AND REGULATIONS PROMULGATED TO GIVE EFFECT TO THE PROVISIONS OF THE INTERNATIONAL TREATIES ON NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES CHILE Communicated by the Government of Chile NOTE BY THE SECRETARY GENERAL - In accordance with the relevant Articles of the International Treaties on Narcotic Drugs and Psychotropic Substances, the Secretary-General has the honour to communicate the following legislative texts. INDEX Page E/NL.1977/26 Regulation No. 4 on Dependence-producing Pharmaceutical Products, 2 January 1970 E/NTJ.1977/27 Order No. 90 of 4 February 1970 - Schedule of products subject to control under the Regulations on Dependence-producing Pharmaceutical Products. 5 E/NLol977/28 Order No. 92 of 19 January 1976 13 Official Gazette No. 27.554 E/NL,1977/26 24 January 1970 Recovery of Health Division Pharmaceutical Section REGULATION NO. 4 ON DEPENDENCE-PRODUCING PHARMACEUTICAL PRODUCTS Santiago, 2 January 1970 Considering the information furnished by the National Health Service in Circular No. 19.892 of 1 October 1969; the reports, recommendations and agreement of the United Nations specialized agencies concerning the harmful effects of abuse of dependence- producing drugs; the provisions of articles 2 and 107 of the Health Code; and the authority conferred on the undersigned by article 72 (2) of the Constitution of Chile, IT IS HEREBY DECREED AS FOLLOWS: The "REGULATIONS ON DEPENDENCE PRODUCING PHARMACEUTICAL PRODUCTS" set out below are adopted: Article 1. The production, manufacture, extraction, preparation, import, export, distribution, possession or ownership, removal for whatever reason, transit, transport and use of hypnotic agents, amphetamines and other stimulants of the central nervous system, meprobamates and all other dependence-producing drugs, shall be subject to the norms contained in these Regulations.
    [Show full text]
  • List of Controlled Drugs and Permitted Quantities)
    1.6 Open General Licence List (List of controlled drugs and permitted quantities) The following are the maximum quantities which may be carried by patients without requiring a licence, provided they carry with them a covering letter from their prescribing doctor. Alphapropine 3600mgs Amphetamine 300mgs Amphetamine Phosphate 225mgs Amphetamine Sulphate 225mgs Anhydrous Morphine 360mgs Anileridine 900mgs Anileridine Hydrochloride 900mgs Anileridine Phosphate 900mgs Benzphetamine 2250mgs Benzitramine 450mgs Buprenorphine (as hydrochloride) Temgesic 24mg Buprenorphine (as hydrochloride) Subutex 140mg Chlorphentermine Hydrochloride 975mgs Cocaine Hydrochloride, Nitrate, or ) 20ml at 4% 4mlSulphate Eyedrops ) maximum strength Cocaine Hydrochloride, Nitrate, or Sulphate ) as active ingredient in a mixture being used ) 500mgs by a patient who is terminally ill. ) Dexamphetamine 300mgs Dexamphetamine Phosphate 150mgs Dexamphetamine Sulphate 900mgs Dextromoramide Tartrate 900mgs Diamorphine Hydrochloride as an ingredient 500mgs ) Permission in a mixture or linctus ) will be needed ) from relevant ) Ministry of Diamorphine Hydrochloride Tablets 450mgs ) Health as Diamorphine Hydrochloride Ampoules 1350mgs ) Diamorphine Diamorphine Hydrochloride Elixir 500mgs ) is illegal in )most of the )world. Diazepam (and all drugs falling within Schedule 4 Part II) 900mgs Diethylpropion Hydrochloride 1125mgs 1 Dihydrocodeine Tartrate 3600mgs ) Not controlled Dihydrcodeine O-carboxymethyloxine 150mgs ) if not injectable ) or tablet strength <100mg Dipipanone 600mgs
    [Show full text]
  • Council of Europe Committee of Ministers (Partial
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies and superseding Resolution AP (77) 1) AND APPENDIX containing the list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 31 October 1982 RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION 1 (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands, the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969 and 5 May 1964, respectively, Considering that, under the terms of its Statute, the aim of the Council of Europe is to achieve a greater unity between its Members for the purpose of safeguarding and realising the ideals and principles which are their common heritage and facilitating their economic and social progress; Having regard to the
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0008748A1 Beyreuther Et Al
    US 200800O8748A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0008748A1 Beyreuther et al. (43) Pub. Date: Jan. 10, 2008 (54) METHOD FOR TREATING PAIN USING A (30) Foreign Application Priority Data SUBSTITUTED 2-AMNOTETRALIN COMPOUND Jun. 22, 2006 (EP).............................. EP O6 O12 815.4 (76) Inventors: Bettina Beyreuther, Dusseldorf (DE); Publication Classification Dieter Scheller, Neuss (DE); Joachim (51) Int. Cl. Freitag, Nurtingen (DE); Josephe A6II 3L/38 (2006.01) Bianchine, Potomac, MD (US) A6II 3L/439 (2006.01) A 6LX 9/70 (2006.01) A6IP 25/04 (2006.01) Correspondence Address: (52) U.S. Cl. ........................... 424/449; 514/289: 514/438 HARNESS, DICKEY, & PIERCE, P.L.C 7700 BONHOMME, STE 400 (57) ABSTRACT ST. LOUIS MO 63105 US 9 (US) A method for treating pain, particularly non-inflammatory musculoskeletal pain Such as fibromyalgia, myofascial pain (21) Appl. No.: 11/764,907 or back pain, in a subject comprises administering to the Subject a substituted 2-aminotetralin compound as defined (22) Filed: Jun. 19, 2007 herein, illustratively rotigotine. vehicle 0.3 mg/kg 1 mg/kg 3 mg/kg rotigotine 100 80 2O - 10-15 time after formalin injection (min) Patent Application Publication Jan. 10, 2008 Sheet 1 of 2 US 2008/0008748A1 vehicle 0.3 mg/kg E 1 mg/kg 3 mg/kg rotigotine 100 6 O 4. O 2 O 10-15 15-20 20-25 25-30 time after formalin injection (min) Fig. 1 vehicle 0.3 mg/kg 1 mg/kg 3 mg/kg rotigotine 300 250 200 15 O 1 O O 5 O O-5 10-30 time after formalin injection (min) Fig.
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]
  • The Barbiturates in Forensic Chemistry Dissertation
    THE BARBITURATES IN FORENSIC CHEMISTRY DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy- in the Graduate School of The Ohio State University EQr GWENDOLYN BERTHA CARSON, B« S., M* A* The Ohio State University 195U Approved by* Department of Physiological Chemistry ___________ i TABLE OP CONTENTS page A« Introduction 1 B» Historical 1. The Barbiturates ---------------- 2 2* Barbiturate Poisoning - - -------------------- U a) Deaths due to Barbiturates in Pour Counties and the United States - - ------ ----- 11 b) Doses of Barbiturates in Grains - - -- - - 16 3* Barbiturate Regulations------- - ------------ 21 C. Isolation of the Barbiturates ----- --- - - --- - 2h D» Qualitative Tests for Barbiturates ----- — - ---- 26 E. Quantitative Methods for Barbiturates -------- 28 F* Examination of Tissues --- — 30 1# Degradation Products of Barbiturates ------ 3 1 2a Percent Recovery of Unchanged Barbiturates - - - 3^ G. Experimental Procedures --------------- 35 1* Effect of 5$ Potassium Hydroxide on Barbiturates- 36 2 . Effect of 20$ Acetic Acid on Barbiturates - - - - 38 3. Effect of Water on Salts of Barbituric Acids - - 38 k» Barbiturates Extracted from Liver with 5$ Potassium Hydroxide - — ___ ip. 5. Barbiturates Extracted from Liver with 20$ Acetic A c i d ------------------------------- Hi 6 . Barbiturates Extracted from Liver at pH 1 0 HU 7. Refractive Indices of Barbiturates - ------- H6 8 . Barbiturate-Cyanide Reaction ---------------- 50 9» Effect of Atmospheric Conditions on Barbiturates-
    [Show full text]